As 2018 European League Against Rheumatism (EULAR) recommendations suggested, for severe and/or refractory intestinal BD patients, monoclonal anti-tumor necrosis factor (TNF) antibodies should be considered [5]. This evidence concerns the gene TNF and Behcet disease.